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Abstract
Objectives
To estimate the prevalence and risk factors for abnormal liver enzymes in a large age- and
gender stratified population-based sample of apparently healthy individuals with or without
alcohol consumption and other health-related risk factors (adiposity, physical inactivity,
smoking).
Methods
Data on alcohol use, smoking, diet and physical activity were recorded using structured
questionnaires from 13,976 subjects (6513 men, 7463 women, aged 25–74 years) in the
national FINRISK studies. Alcohol data was used to categorize the participants into abstain-
ers, light drinkers, moderate drinkers and heavy drinkers. Serum gamma-glutamyltransfer-
ase (GGT) and alanine aminotransferase (ALT) activities were measured using standard
kinetic methods.
Results
Male light drinkers, moderate drinkers and heavy drinkers showed significantly higher rela-
tive risks of abnormal GGT than abstainers: 1.37 (95% confidence interval 1.11 to 1.71, p <
0.01), 2.72 (2.08 to 3.56, p < 0.0005), and 6.10 (4.55 to 7.17, p < 0.0005), respectively. Cor-
responding values for women were 1.22 (0.99 to 1.51, p = 0.065), 1.90 (1.44 to 2.51, p <
0.0005), and 5.91 (3.80 to 9.17, p < 0.0005). Estimated threshold doses for a significant
GGT elevation was 14 standard weekly alcohol doses for men and 7 for women. Excess
body weight and age over 40 years modulated the thresholds towards smaller quantities of
alcohol. The risk of abnormal GGT was also significantly influenced by physical inactivity
and smoking. The relative risks of abnormal ALT activities were increased in male heavy
drinkers, especially in those presenting with adiposity and sedentary lifestyle.
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Conclusions
Alcohol use markedly increases the risk for abnormal liver enzyme activities in those pre-
senting with age over 40 years, obesity, smoking or sedentary lifestyle. The data should be
considered in public health recommendations and in the definitions of safe limits of alcohol
use.
Introduction
Alcohol consumption accounts for a significant proportion of life years lost to disability [1–3].
Based on scientific evidence about the harmful consequences of alcohol drinking, the defini-
tion of heavy or at-risk drinking has been rapidly evolving over the past two decades. The data
gathered so far has also prompted revisions of governmental guidelines in several countries [2,
4–6]. In current societies approximately every sixth adult individual have been estimated to
drink alcohol in amounts, which exceed the limits that are known to increase the risk of multi-
ple medical problems (24 standard drinks of alcohol per week for men and 16 drinks for
women) [1, 4, 5]. However, the health risks resulting from consumption of more modest
amounts of alcohol and the issue of safe limits of alcohol use have remained as matters of long-
standing controversy.
Recently, evidence has accumulated to indicate that even light to moderate alcohol drinking
may increase the risk of certain cancers [6–8] and adverse brain outcomes in long-term fol-
low-ups [9]. Studies have further indicated that the activities of common liver enzymes, ALT
and GGT, may increase from baseline as a result of relatively low alcohol drinking levels espe-
cially in individuals with adiposity [10–13]. With epidemic levels of both obesity and excessive
alcohol intake doctors are currently encountering increasing numbers of abnormal liver func-
tion tests which may indicate silent liver disease [2, 10, 14]. The early changes in the activities
of liver enzymes in such patients may also predict both hepatic and extra-hepatic health risks,
including metabolic syndrome, and cardio- or cerebrovascular events [15–17]. Changes in
GGT activities appear to be mechanistically linked with the activation of oxidative stress [18–
20], whereas serum ALT rather marks disturbed liver cell integrity or cellular adaptation to
maintain energy homeostasis [21, 22].
Recent advances in individualized medicine have also emphasized a more systematic use of
biomarker data for the assessment of lifestyle and dietary interventions aimed at reducing dis-
orders caused by hazardous drinking or excess body weight [1, 10, 23]. A more widespread use
of laboratory tests has, however, been hampered by the lack of uniform definitions of bio-
marker normal ranges for even the most commonly used biomarkers, such as liver enzymes,
and lack of knowledge on the safe limits of alcohol intake [24, 25]. There is also a paucity of
studies observing the relationships between mild to moderate levels of alcohol drinking and
the early-phase changes in liver enzymes in large populations stratified by key covariates [10,
25].
In the present study we collected data from a large national FINRISK population health sur-
vey to determine the relative risks of abnormal liver enzyme findings in apparently healthy
individuals with detailed records on alcohol consumption, diet and other health-related behav-
iour, including physical activity. The recently established ULNs for liver enzymes based on
abstainers with normal body weight were used as reference [11]. The purpose of the study was
to offer new perspectives on the relationships between alcohol use, adiposity, sedentary life
style and liver enzyme abnormalities, which would have important implications for public
health.
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Materials and methods
Participants
Data was collected from a cross-sectional population health survey (The National FINRISK
study) carried out in six different geographic areas in Finland in years 1997, 2002, and 2007.
This survey was originally set out to examine risk factors of chronic, non-communicable dis-
eases and modifiable behavioural risk factors. For this purpose, an age- and gender stratified
random sample was drawn from the population register according to an international WHO
MONICA (Monitoring trends and determinants in cardiovascular disease) protocol [26]. The
clinical examinations included physical measurements, laboratory tests and detailed question-
naires encompassing alcohol intake, current health status, diet, smoking, current physical activ-
ity, medical history and socioeconomic factors [26–28]. Body weight and height were measured
to the nearest 0.1 kg and 0.1 cm, respectively. Body mass index (BMI, kg/m2) was calculated as a
measure of relative body weight. Waist circumference was measured to the nearest 0.5 cm
between the lowest rib and the iliac crest while the subject was at minimal respiration.
The subjects included were devoid of any clinical signs of liver disease, ischaemic heart or
brain disease, diabetes or abnormal glucose tolerance test, hypertension or active infection at
the time of the study. The final study population consisted of 13,976 apparently healthy indi-
viduals: 6513 men and 7463 women (mean age 45 ± 13 years, range 25–74 years) who com-
pleted the questionnaires and attended the medical examinations. The response rates in the
1997, 2002 and 2007 surveys were 73.4%, 71.4% and 66.9%, respectively. Alcohol consumption
was assessed with structured questionnaires including information on the type of beverage
consumed and the quantity and frequency of consumption using a retrospective recall method
registering consumption from the past weeks and one year prior to blood sampling [28, 29].
The amount of ethanol in different beverages was quantitated based on defined portion sizes
as follows: regular beer 12 grams (1/3 L), strong beer 15.5 grams (1/3 L), long drink 15.5 grams
(1/3 L), spirit 12 grams (4 cL), wine 12 grams (12 cL) and cider 12 grams (1/3 L). A dose of 12
grams of pure ethanol was considered as one standard drink.
The data on alcohol consumption was subsequently used to categorize the population by
gender and drinking habits as follows: 1. persons who reported no current alcohol consump-
tion were referred to as non-drinkers (abstainers), 2. light drinkers consumed between 1–13
drinks (men) or 1–6 drinks (women), 3. moderate drinkers consumed 14–23 drinks (men) or
7–15 drinks (women) and 4. heavy drinkers consumed more than 23 drinks (men) or more
than 15 drinks (women) per week. In the assessment of relative risks of abnormal liver enzyme
activities in more detail the category of light drinkers was further separated into subgroups of
very light drinkers: men < 7 (n = 2166), women < 3.5 (n = 2092) drinks per week and light
drinkers men 7 and< 14 (n = 1436), women 3.5 and< 7 (n = 1200) drinks per week.
Smoking and coffee consumption were assessed with a set of standardized questions and
expressed as the amount of cigarettes per day and as the intake of standard servings of coffee
(cups) per day, respectively. Physical activity and the number and total time used for physical
exercises were registered using structured questionnaires [28, 30]. The data was used to classify
the population into the subgroups of 1. moderate or vigorous activity (over 4 hours of activity
per week including brisk running, walking, cross-country skiing, swimming or other strenu-
ous exercises) 2. light (0.5–4 hours per week including walking, cycling, gardening or other
moderate activities), and 3. sedentary activity (less than 0.5 hours per week).
All surveys were conducted in accordance with the Declaration of Helsinki according to the
ethical rules of the National Public Health Institute. Written informed consent was obtained
from all participants. The approval for this study was received from the Coordinating Ethics
Committee of the Helsinki Hospital District.
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Laboratory analyses
Serum ALT and GGT were measured by standard kinetic methods following recommenda-
tions of the European Committee for Clinical Laboratory Standards (ECCLS) on an Abbott
Architect clinical chemistry analyser (Abbott Laboratories, Abbott Park, IL, USA).
Statistical methods
Values are expressed as mean ± SD or mean ± 95% confidence interval (CI). Comparisons in
the distribution of the data were carried out with a chi square test for trend and pr-test on the
equality of proportions using Stata statistical data analysis software (StataCorp LP, TX, USA).
For comparisons between groups, Student’s t-test or ANOVA with Tukey’s HSD as a post hoc
test for multiple factors were used. ANOVA with Dunnett post hoc test was used to determine
the threshold levels of alcohol doses for initiating a significant elevation in liver enzymes based
on the data with a separate category for each weekly standard drink. Logistic regression was
used to assess whether drinking status and the covariates associated with the abnormal liver
enzyme levels. Both univariable and multivariable analyses were performed and the results of
multivariable analyses are reported. In the analyses the participants with missing data were list-
wise excluded. The analyses were carried out with IBM SPSS Statistics 22.0 (Armonk, NY:
IBM Corp.). A p-value < 0.05 was considered statistically significant.
Results
The main demographic characteristics and lifestyle factors of the participants classified to sub-
groups according to alcohol consumption and gender are summarized in Table 1. Among
men, 26.0% of the population were abstainers, 55.3% were light drinkers, 12.0% were moderate
drinkers and 6.7% were heavy drinkers. In women the corresponding percentages were 41.2%,
44.1%, 12.7%, and 2.0%.
Table 1. Main characteristics of the study population, as classified according to drinking status.
Men Abstainers Light drinkers Moderate drinkers Heavy drinkers
Alcohol consumption 0 drinks/week 1–13 drinks/week 14–23 drinks/week  24 drinks/week
N (%) 1696 (26.0) 3602 (55.3) 780 (12.0) 435 (6.7)
Age, years, mean ± SD 46.1 ± 13.8 (n = 1696) 44.8 ± 12.9 (n = 3602) 44.0 ± 11.9 (n = 780) 44.8 ± 11.3 (n = 435)
BMI 26.3 ± 3.8 (n = 1554) 26.2 ± 3.5 (n = 3279) 26.6 ± 3.9 (n = 699) 26.9 ± 4.4 (n = 382)
Waist circumference, cm 92.8 ± 10.9 (n = 1554) 92.6 ± 10.2 (n = 3267) 94.2 ± 11.2 (n = 696) 96.3 ± 12.4 (n = 380)
Smoking, cigarettes/day 4.3 ± 8.8 (n = 1685) 4.4 ± 8.1 (n = 3562) 8.0 ± 10.2 (n = 773) 11.4 ± 12.6 (n = 426)
Coffee, cups/day 4.8 ± 3.6 (n = 1670) 4.7 ± 3.1 (n = 3571) 5.1 ± 3.4 (n = 780) 4.9 ± 4.0 (n = 430)
Physical activity, number of exercises/week 2.5 ± 2.2 (n = 600) 2.3 ± 1.9 (n = 1366) 2.0 ± 2.1 (n = 328) 2.0 ± 2.3 (n = 166)
Women Abstainers Light drinkers Moderate drinkers Heavy drinkers
Alcohol consumption 0 drinks/week 1–6 drinks/week 7–15 drinks/week  16 drinks/week
N (%) 3072 (41.2) 3292 (44.1) 947 (12.7) 152 (2.0)
Age, years, mean ± SD 44.3 ± 13.5 (n = 3072) 43.8 ± 12.2 (n = 3292) 42.4 ± 11.4 (n = 947) 45.4 ± 10.8 (n = 152)
BMI 25.8 ± 4.8 (n = 2818) 25.1 ± 4.4 (n = 3022) 24.9 ± 4.0 (n = 851) 25.6 ± 4.1 (n = 125)
Waist circumference, cm 82.0 ± 12.1 (n = 2722) 80.5 ± 11.3 (n = 3010) 80.6 ± 10.9 (n = 849) 83.6 ± 10.8 (n = 125)
Smoking, cigarettes/day 2.0 ± 5.3 (n = 3059) 2.1 ± 5.2 (n = 3274) 3.9 ± 6.4 (n = 937) 8.7 ± 9.0 (n = 149)
Coffee, cups/day 3.7 ± 2.6 (n = 3038) 3.7 ± 2.5 (n = 3281) 3.8 ± 2.5 (n = 940) 3.8 ± 2.4 (n = 152)
Physical activity, number of exercises/week 2.5 ± 2.1 (n = 1146) 2.6 ± 2.1 (n = 1300) 2.3 ± 1.9 (n = 394) 2.7 ± 2.4 (n = 62)
BMI, body mass index
https://doi.org/10.1371/journal.pone.0188574.t001
Safe limits of alcohol consumption based on liver enzyme abnormalities
PLOS ONE | https://doi.org/10.1371/journal.pone.0188574 December 5, 2017 4 / 15
The upper normal limits used for ALT and GGT were based on previously described values
defined by calculating 97.5th percentiles of the data based on normal weight non-drinkers [11].
The amount of alcohol (mean ± SD) consumed in those exceeding the ULNs in GGT analyses
in the present population was 170 ± 206 grams per week for men and 55 ± 78 grams per week
for women (Table 2). For ALT, the corresponding levels were 144 ± 194 grams per week for
men and 42 ± 63 grams per week for women (Table 2).
Fig 1 shows the frequencies of abnormal liver enzymes from the different subgroups classi-
fied according to drinking status. In men, abnormal GGT findings were significantly more fre-
quent in light drinkers (10.9%) (p < 0.01), moderate drinkers (21.8%) (p< 0.001) and heavy
drinkers (40.6%) (p< 0.001) than in abstainers (8.7%). In women, the likelihood of abnormal
GGT findings was increased in moderate drinkers (10.6%) (p< 0.001) and in heavy drinkers
(31.2%) (p< 0.001) when compared to abstainers (6.7%) or light drinkers (7.2%) (p< 0.001
for each comparison). For ALT, the group of heavy drinkers showed abnormal values more
frequently than the group of abstainers (p< 0.001 for men, p< 0.01 for women) (Fig 1).
In the analyses of the incidences of abnormal liver enzyme values based on alcohol con-
sumption reported from the past 12 months, the estimates of weekly alcohol consumption
were found to be in good agreement with the estimates obtained from the data on more recent
drinking (r = 0.664, p< 0.0001). The incidences of elevated liver enzymes were, however,
higher in the subgroups classified as heavy drinkers based on the latter approach (Fig 1) than
in the corresponding subgroups formed based on 12-mo data (GGT: 31.4% men, 26.5%
women; ALT 21.1% men, 12.8% women). No significant differences occurred in the corre-
sponding comparisons of abstainers, light drinkers or moderate drinkers. The individuals who
could be classified as former drinkers (n = 314, 159 men, 155 women) reporting previous alco-
hol consumption but no alcohol consumption from the past 12 months showed low rates of
elevated liver enzyme values (GGT: 7.1% men, 2.4% women; ALT 6.0% men, 1.4% women).
The estimated threshold alcohol doses for initiating a significant elevation in GGT activities
were 14 standard drinks of weekly alcohol consumption for men and 7 drinks for women (Fig
2). Excess body weight and increasing age were found to modulate the thresholds towards
smaller quantities (Fig 3).
Table 3 summarizes the multivariable relative risks of abnormal GGT and ALT findings
according to drinking habits, age, waist circumference, physical activity and smoking. When
compared with abstainers, male light drinkers, moderate drinkers and heavy drinkers had rela-
tive risks of abnormal GGT activities of 1.37 (95% confidence interval 1.11 to 1.71, p< 0.01),
2.72 (2.08 to 3.56, p< 0.0005), and 6.10 (4.55 to 7.17, p< 0.0005), respectively. Corresponding
values for women were 1.22 (0.99 to 1.51, p = 0.065), 1.90 (1.44 to 2.51, p< 0.0005), and 5.91
(3.80 to 9.17, p< 0.0005). When the category of light drinkers was further separated into sub-
groups of very light drinkers (men < 7, women < 3.5 drinks per week) and light drinkers
Table 2. Mean alcohol consumption (grams per week) in groups according to laboratory test ULN.
< ULN  ULN
mean ± SD mean ± SD p
GGT
Men 82.1 ± 110.1 170.3 ± 206.3 < 0.0005
Women 33.7 ± 50.8 54.6 ± 78.4 < 0.0005
ALT
Men 91.1 ± 122.4 144.0 ± 193.9 < 0.0005
Women 35.1 ± 50.4 41.8 ± 62.9 0.160
GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; ULN, upper limit of normal
https://doi.org/10.1371/journal.pone.0188574.t002
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(men 7 and< 14, women 3.5 and< 7 drinks per week) the relative risks for abnormal
activities were not found to be increased in any of the comparisons among very light drinkers
(data not shown).
Fig 1. Incidence of abnormal GGT and ALT activities in groups classified according to drinking
status.
https://doi.org/10.1371/journal.pone.0188574.g001
Fig 2. Estimated threshold doses of alcohol consumption (standard drinks /week) for initiating a
significant GGT activation. The levels leading to GGT increases especially in those above 40 years of age
are markedly lower than the current limits of heavy drinking in many Western countries (men: 24 drinks,
women: 16 drinks) (dashed line).
https://doi.org/10.1371/journal.pone.0188574.g002
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The risk of abnormal GGT was found to be significantly influenced by age, adiposity, physi-
cal activity and smoking (Table 3). For ALT, the relative risks of abnormal activities were
increased only in male heavy drinkers. Adiposity and sedentary lifestyle also increased the like-
lihood of abnormal ALT levels (Table 3). The individuals with low or sedentary physical activ-
ity showed markedly higher relative risks for elevated liver enzymes than those engaged in
physically demanding activities for at least 3 hours per week.
Fig 3. Serum GGT and ALT in subgroups classified according to drinking status, age and BMI. Data
are shown as median and interquartile ranges.
https://doi.org/10.1371/journal.pone.0188574.g003
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The analysis of the associations between coffee consumption and the risk for elevated liver
enzyme values showed that GGT activities in those classified as heavy drinkers (whereas not in
other drinking categories) were also significantly influenced by coffee drinking. Heavy drink-
ers consuming 4 cups of coffee showed significantly lower GGT levels (men 65 ± 74 U/L,
women 41 ± 76 U/L) than the corresponding groups consuming 1–3 cups (men 91 ± 90 U/L,
women 62 ± 120 U/L) or no coffee (men 120 ± 171 U/L, women 76 ± 95 U/L) (p< 0.001 for
comparisons in both genders).
Discussion
In this large cross-sectional population-based sample of apparently healthy individuals, we
showed that the relative risk of abnormal liver enzyme activities is increased in individuals
consuming alcohol in amounts considered as light to moderate drinking levels. In light of
Table 3. Relative risks of abnormal liver enzyme levels in study subgroups from a cross-sectional FINRISK population survey.
GGT ALT
Men Women Men Women
Multivariable
relative risk
p Multivariable
relative risk
p Multivariable
relative risk
p Multivariable
relative risk
p
Drinking status
Abstainers
Light drinkers 1.37 (1.11 to 1.71) 0.004 1.22 (0.99 to 1.51) 0.065 1.09 (0.78 to 1.53) 0.614 1.08 (0.76 to 1.52) 0.666
Moderate drinkers 2.72 (2.08 to 3.56) < 0.0005 1.90 (1.44 to 2.51) < 0.0005 1.19 (0.74 to 1.90) 0.481 1.27 (0.78 to 2.07) 0.344
Heavy drinkers 6.10 (4.55 to 8.17) < 0.0005 5.91 (3.80 to 9.17) < 0.0005 3.10 (1.86 to 5.15) < 0.0005 2.23 (0.94 to 5.33) 0.070
Age groups
< 40 yrs
40–49 yrs 1.27 (1.03 to 1.57) 0.026 1.75 (1.34 to 2.29) < 0.0005 0.91 (0.66 to 1.26) 0.563 0.96 (0.63 to 1.45) 0.838
50–64 yrs 1.23 (1.00 to 1.51) 0.051 2.70 (2.10 to 3.47) < 0.0005 0.35 (0.24 to 0.51) < 0.0005 1.36 (0.93 to 1.97) 0.109
> 64 yrs 0.65 (0.46 to 0.93) 0.019 2.83 (1.99 to 4.02) < 0.0005 0.17 (0.07 to 0.44) < 0.0005 0.39 (0.14 to 1.10) 0.074
Waist circumference
Low risk *
High risk ** 2.67 (2.19 to 3.27) < 0.0005 1.54 (1.20 to 1.97) 0.001 3.08 (2.19 to 4.34) < 0.0005 1.69 (1.12 to 2.54) 0.012
Very high risk *** 5.07 (4.12 to 6.24) < 0.0005 3.07 (2.45 to 3.84) < 0.0005 6.00 (4.26 to 8.46) < 0.0005 3.28 (2.25 to 4.78) < 0.0005
Physical activity
Moderate/vigorous
(reference)
Light 1.37 (1.11 to 1.69) 0.004 1.46 (1.12 to 1.89) 0.005 1.49 (1.03 to 2.15) 0.033 0.85 (0.58 to 1.25) 0.406
Sedentary 1.51 (1.18 to 1.93) 0.001 1.55 (1.15 to 2.10) 0.004 1.96 (1.31 to 2.93) 0.001 0.83 (0.51 to 1.33) 0.437
Smoking
No smoking
1–9 cigarettes/day 1.03 (0.74 to 1.44) 0.869 1.26 (0.90 to 1.77) 0.179 1.26 (0.78 to 2.03) 0.350 1.02 (0.59 to 1.77) 0.954
10–19 cigarettes/
day
1.24 (0.97 to 1.58) 0.093 1.22 (0.91 to 1.65) 0.189 1.10 (0.73 to 1.65) 0.651 0.69 (0.40 to 1.19) 0.183
20–29 cigarettes/
day
1.61 (1.26 to 2.05) < 0.0005 1.12 (0.70 to 1.79) 0.635 0.79 (0.51 to 1.24) 0.303 0.40 (0.12 to 1.30) 0.128
 30 cigarettes/day 1.56 (1.06 to 2.30) 0.024 2.05 (0.87 to 4.86) 0.102 0.81 (0.40 to 1.63) 0.549 4.14 (1.01 to 16.92) 0.048
GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase
*, men < 94 cm, women < 80 cm
**, men 94–102 cm, women 80–88 cm
***, men > 102 cm, women > 88 cm
https://doi.org/10.1371/journal.pone.0188574.t003
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recent findings indicating that the early changes in the activities of GGT and ALT should also
be regarded as important prognostic markers of both hepatic and extra-hepatic health risks
[17, 19, 22], it may be assumed that the risk categories of alcohol drinking and associated indi-
vidual health-related behaviour need further attention.
The large number of well-characterized study subjects offered us with the possibility to per-
form a comprehensive analysis of the relative risks of abnormal biomarker findings across all
levels of alcohol consumption and other factors of lifestyle. Our study relied largely on the data
obtained from common liver enzymes, ALT and GGT, both of which are readily induced by
excessive alcohol consumption and are associated with relevant clinical outcomes. These liver
enzymes may also be considered biomarkers of choice since they are easily measurable, cost-
effective and easy to interpret by clinicians. Although current progress in clinical laboratories
and quality control regimes has led to more consistent measurement procedures, several prac-
tical problems have remained unresolved including definitions of universal normal ranges.
The ULNs for even the most commonly used biomarkers for liver status, ALT and GGT, cur-
rently show significant variation between individual laboratories and geographic areas [11, 25,
31, 32]. Thus, there is a continuing need for additional biomarker validation to translate the
numerical values into clinically meaningful information, which would also allow more efficient
international comparisons of the data.
Over the past decades reduction of harmful alcohol drinking has been an important target
for public health policies. Although heavy alcohol use is known to be causally linked to over 60
distinct diseases, the association between light to moderate drinking and the overall risk of
health problems has remained unclear [1, 5]. The concepts of beneficial, safe or harmful levels
of ethanol intake have also remained as topics of great interest and lively debate. While other
studies have suggested that light to moderate drinking is associated with beneficial health
effects especially in those following a Mediterranean diet [33], other groups of investigators
have not reached similar conclusions [34–36]. The questions on the dose-effect relationships
between ethanol intake, biomarker changes and possible tissue injury have also remained
unresolved. The present data supports the view that biochemical responses in the sequence of
events leading to health problems may be expected to occur even in association with light to
moderate drinking levels especially in those with precipitating risk factors. Recent findings by
other groups of investigators have also emphasized the view that light to moderate drinking
could be associated with an elevated risk of cancer [6–8], atrial fibrillation [37], left ventricular
diastolic dysfunction [38], adverse brain outcomes [9] and an increase in all-cause mortality
[39]. Although reductions in alcohol-attributable disease burden may obviously be expected to
be achieved through a more efficient identification of high-risk individuals, alcohol-consum-
ing patients seem rarely receive specific intervention in current clinical practice unless the situ-
ation is complicated by comorbidity.
The present data indicates that the influence of ethanol on liver enzymes is significantly
driven by factors such as gender, age, excess body weight, physical inactivity or smoking,
which should all be taken into account when discussing individually on the most appropriate
levels of drinking. Although the primary mechanisms underlying such observations remain
unknown at this time it is possible that all these conditions stimulate oxidative stress in an
additive, gender- and age-dependent manner. GGT enzyme plays a pivotal role in the metabo-
lism of glutathione (GSH), and elevated activities could sign a need to maintain intracellular
GSH levels during oxidative stress [11, 15, 40–44]. While alcohol use and related harm are
more prevalent in men, women seem to show elevated liver enzyme activities following con-
sumption of smaller amounts of alcohol. In accordance with previous findings, alcohol con-
sumption in those above 40 years of age appears to pose a higher risk towards elevated GGT
levels [23], which could indicate a greater sensitivity towards oxidative stress upon aging or
Safe limits of alcohol consumption based on liver enzyme abnormalities
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more prolonged alcohol exposure in such individuals [41, 45]. Unfortunately, quantitative
data on lifetime exposure to ethanol was not available in this survey to test this hypothesis.
The presence of adiposity was also found to be an important driving force for abnormal
liver enzymes. There may also be additive effects of excess body weight and alcohol use [46–
48]. Recent studies have shown that the risk of non-alcoholic fatty liver disease (NAFLD)
increases with both increasing levels of average daily alcohol consumption and increasing BMI
[49]. The adverse effects of ethanol on the liver are also aggravated by high-fat-diets in experi-
mental animal models [50]. Since in real life situations alcohol use often co-exists with obesity,
synergistic health problems and metabolic comorbidities due to these two triggers may be
expected to occur in an ever-increasing manner together with an increasing occurrence of
abnormal liver function tests in the affected individuals [12, 13, 47, 51, 52]. Lifestyle and die-
tary therapies play a pivotal role in reversing the course of such conditions and consequently,
there may be an increasingly important role of liver enzymes in monitoring treatment based
on behavior change. There may also be emerging new applications for these enzymes as overall
health indicators including health problems outside the liver [19]. Increases in ALT and GGT
levels have been shown to predict deposition of triglycerides and fat in tissues and to increase
extra-hepatic health risks, such as type 2 diabetes, metabolic syndrome, insulin resistance and
cardio- or cerebrovascular events [15, 17, 19, 52–58]. Due to the ability of GGT to trigger iron-
dependent oxidation of LDL in coronary plaques, studies have also proposed a role for GGT as
a mechanistic link between fatty liver and atherosclerosis [55].
Physical inactivity is an increasingly common contributor to poor health across the world
[59, 60]. Here physical inactivity and sedentary behaviour were found to markedly increase the
risk for elevated liver enzymes supporting also the view that improvement of metabolic health
through physical exercise could serve as a therapeutic approach to provide protection from the
harmful consequences of alcohol and diet-induced adverse metabolic and obesogenic effects.
The individuals engaged in physically demanding activities for at least 3 hours per week
showed markedly lower risks for elevated liver enzymes than those with low or sedentary activ-
ity. It remains to be established whether physical exercise could also confer long-term benefits
to hepatic health and alcohol-attributable disease burden in general [61–63].
In accordance with recent data by other groups of investigators [64] the present observa-
tions also point to a significant synergistic effect of smoking and alcohol use in increasing
GGT levels. Smoking was more common in heavy drinkers of alcohol and it appears that the
combination of heavy drinking and smoking also leads to additive hepatotoxic effects, espe-
cially in men [64, 65]. In addition, coffee consumption was found to interact with alcohol con-
sumption and GGT levels such that a high intake of coffee in heavy alcohol drinkers was more
likely to be associated with lower GGT levels than those in the corresponding group of heavy
drinkers consuming no coffee. This observation points to a possible protective effect of coffee
drinking towards alcohol-induced liver damage [66, 67]. However, in the present material the
amount of coffee intake required for significant effects in GGT activities in heavy drinkers was
higher ( 4 cups per day) than the recent estimates for the hepatoprotective effects of coffee in
U.S. National Health and Nutrition Examination Survey ( 3 cups per day) Xiao et al. [67] or
in the Singapore Chinese Health study ( 2 cups per day) [68].
The primary strengths of the current study include the large number of participants,
detailed assessments of risk factors, standardized evaluation of alcohol consumption and other
risk profiles as well as parallel assessments in men and women. The cross-sectional setting of
the survey can be kept as a limitation of this study since lack of follow-up data prevents analy-
ses on the specific relationships between changes in liver enzyme activities and duration of
drinking or indices of adiposity. It is also possible that the alcohol recall techniques may lead
to underestimation of alcohol intake and overestimate the proportion of those not drinking
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alcohol at all [29, 69]. This would, however, rather lead to diluting effects to the observed
results and the real associations and interactions might be even stronger. It should further be
noted that previous studies have emphasized the importance of differentiating between former
drinkers, current drinkers and abstainers in studies evaluating health-related effects of alcohol
drinking [70]. In our analyses, the individuals who could be classified as former drinkers with
no alcohol consumption during the past one year prior to sampling showed low rates of abnor-
mal values underscoring the impact of successful behavioural changes in improving liver
health.
Taken together, our study provides a comprehensive assessment of the relationships
between alcohol intake and risk of abnormal liver enzyme levels, which may occur even at
light to moderate levels of drinking in an age-, gender-, BMI-, and physical activity dependent
manner. Current data should be considered in public health recommendations and in the defi-
nition of safe limits of ethanol intake.
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